journal
MENU ▼
Read by QxMD icon Read
search

Therapeutic Advances in Urology

journal
https://www.readbyqxmd.com/read/28588653/renal-cell-carcinoma-with-inferior-vena-cava-thrombus-extending-to-the-right-atrium-diagnosed-during-pregnancy
#1
REVIEW
Efe C Ghanney, Jaime A Cavallo, Matthew A Levin, Ramachandra Reddy, Jeffrey Bander, Maria Mella, Joanne Stone, Myron Schwartz, Kenneth Haines, Umesh Gidwani, Reza Mehrazin
Only one case of renal cell carcinoma (RCC) with inferior vena cava (IVC) tumor thrombus diagnosed and treated during pregnancy has been reported in the literature. In that report, the tumor thrombus extended to the infrahepatic IVC (level II tumor thrombus). In the present case, a 37-year-old woman with lupus anticoagulant antibodies was diagnosed with RCC and IVC tumor thrombus extending to the right atrium (level IV tumor thrombus) at 24 weeks of pregnancy. The fetus was safely delivered by cesarean section at 30 weeks of gestation...
December 2017: Therapeutic Advances in Urology
https://www.readbyqxmd.com/read/28588652/efficacy-and-safety-of-daily-mirabegron-50-mg-in-male-patients-with-overactive-bladder-a-critical-analysis-of-five-phase-iii-studies
#2
Andrea Tubaro, José E Batista, Victor W Nitti, Sender Herschorn, Christopher R Chapple, Mary Beth Blauwet, Emad Siddiqui, Moses Huang, Matthias Oelke
BACKGROUND: Oral pharmacotherapies to treat overactive bladder (OAB) are used less in men despite a similar prevalence of storage symptoms as women. The efficacy and safety of once-daily mirabegron 50 mg was evaluated in male OAB patients from five phase III studies that included placebo or antimuscarinic (tolterodine ER 4 mg or solifenacin 5 mg) as a comparator. METHODS: Three pooled 12-week placebo-controlled studies (mirabegron 50 mg versus placebo) and one 12-week non-inferiority phase IIIb study (BEYOND; mirabegron 50 mg versus solifenacin 5 mg) were used for efficacy (daily micturition frequency, urgency and incontinence episodes) and safety analyses...
December 2017: Therapeutic Advances in Urology
https://www.readbyqxmd.com/read/28588651/testosterone-suppression-with-a-unique-form-of-leuprorelin-acetate-as-a-solid-biodegradable-implant-in-patients-with-advanced-prostate-cancer-results-from-four-trials-and-comparison-with-the-traditional-leuprorelin-acetate-microspheres-formulation
#3
Mladen Solarić, Anders Bjartell, Ursula Thyroff-Friesinger, Davide Meani
BACKGROUND: There are two slow-release ready-to-use forms of leuprorelin acetate (1-month and 3-month) that are available as solid, biodegradable implants for the treatment of advanced, hormone-sensitive prostate cancer. These implants have been shown to be as effective as traditional leuprorelin acetate microspheres for achieving successful testosterone suppression (⩽0.5 ng/ml) and lowering prostate-specific antigen (PSA) levels. Here we further evaluate testosterone suppression levels from four clinical trials evaluating the 3-month leuprorelin implant, including analysis below the European Association of Urology (EAU) castration level (<0...
December 2017: Therapeutic Advances in Urology
https://www.readbyqxmd.com/read/28588649/late-recurrence-of-colorectal-adenocarcinoma-as-a-renal-tumour-by-direct-spread-via-the-ureter
#4
Désirée Louise Dräger, Chris Protzel, Andreas Erbersdobler, Oliver Hakenberg
No abstract text is available yet for this article.
October 2017: Therapeutic Advances in Urology
https://www.readbyqxmd.com/read/28588648/strategies-to-minimize-readmission-rates-following-major-urologic-surgery
#5
REVIEW
Janet Baack Kukreja, Ashish M Kamat
Readmissions after major surgical procedures are prevalent across multiple disciplines. Specifically, in urology, with incorporation of early discharge and recovery pathways, readmissions are emerging as an important problem and effecting an epidemic proportion of urology patients. As expected, readmissions have garnered the attention of major healthcare payers in the United States who see readmissions as easy targets because of the association with astronomical costs. More importantly, readmissions have a significant negative impact on patient sense of wellbeing, and places economic and other hardships on the doors of our patients and their families...
October 2017: Therapeutic Advances in Urology
https://www.readbyqxmd.com/read/28588647/an-update-on-best-practice-in-the-diagnosis-and-management-of-post-prostatectomy-anastomotic-strictures
#6
REVIEW
Nicholas R Rocco, Jack M Zuckerman
Postprostatectomy vesicourethral anastomotic stenosis (VUAS) remains a challenging problem for both patient and urologist. Improved surgical techniques and perioperative identification and treatment of risk factors has led to a decline over the last several decades. High-level evidence to guide management is lacking, primarily relying on small retrospective studies and expert opinion. Endourologic therapies, including dilation and transurethral incision or resection with or without adjunct injection of scar modulators is considered first-line management...
October 2017: Therapeutic Advances in Urology
https://www.readbyqxmd.com/read/28588646/the-effects-of-tolterodine-on-anterior-segment-and-choroidal-thickness-in-patients-with-overactive-bladder-syndrome
#7
Hande Hüsniye Telek, Omer Gokhan Doluoglu, Ayse Burcu, Gulizar Demirok, Firdevs Ornek, Ali Ayyildiz
BACKGROUND: To evaluate the effects of tolterodine on anterior segment and choroidal thickness by using the Pentacam system and optical coherence tomography (OCT) (Pentacam). METHODS: A total of 122 eyes of 61 patients (34 female; 27 male) were included in the study. All patients underwent a regular ocular examination and intraocular pressure measurements before and after 3 months of antimuscarinic drug tolterodine treatment, in addition, pupil diameter, anterior chamber depth, anterior chamber volume, anterior chamber angle, and lens thickness were measured through Pentacam (Oculus Inc...
October 2017: Therapeutic Advances in Urology
https://www.readbyqxmd.com/read/28932276/contemporary-best-practice-in-the-evaluation-and-management-of-stuttering-priapism
#8
REVIEW
Georgios Kousournas, Asif Muneer, David Ralph, Evangelos Zacharakis
Stuttering priapism is rare and under-investigated clinical entity. Although it shares similarities with ischaemic priapism, by definition, stuttering priapism has distinct characteristics that advocate for a different management in the clinical setting. Therefore, the management of stuttering priapism aims primarily to prevent recurrence rather than the resolution of spontaneous attacks. A multimodal approach and the individualization of each case are essential because of the diversity of the condition and the plethora of proposed therapeutic strategies...
September 2017: Therapeutic Advances in Urology
https://www.readbyqxmd.com/read/28932275/current-trends-in-percutaneous-nephrolithotomy-an-internet-based-survey
#9
Abd Alrahman Ahmad, Omar Alhunaidi, Mohamed Aziz, Mohamed Omar, Ahmed M Al-Kandari, Ahmed El-Nahas, Mohamed El-Shazly
BACKGROUND: The aim of this study was to report current practices of percutaneous nephrolithotomy (PCNL) among endourologists. METHODS: An internet survey was administered to Endourological Society members. Responders were distributed into three groups according to the number of PCNL cases per year (<50, 50-100, >100). PCNL technical details as well as opinions regarding specific clinical case scenarios were evaluated and compared between groups. RESULTS: We received 300 responses from 47 different countries...
September 2017: Therapeutic Advances in Urology
https://www.readbyqxmd.com/read/28747997/corrigendum
#10
(no author information available yet)
[This corrects the article DOI: 10.1177/1756287217701665.].
July 2017: Therapeutic Advances in Urology
https://www.readbyqxmd.com/read/28747996/triptorelin-for-the-relief-of-lower-urinary-tract-symptoms-in-men-with-advanced-prostate-cancer-results-of-a-prospective-observational-grouped-analysis-study
#11
Thierry Gil, Fouad Aoun, Patrick Cabri, Valérie Perrot, Roland van Velthoven
BACKGROUND: Lower urinary tract symptoms (LUTSs) may develop in men with prostate cancer (PCa) and can impact quality of life (QoL). Gonadotropin-releasing hormone (GnRH) agonists as androgen deprivation therapy are standard treatment for PCa, however, data are limited on their effects on LUTSs. A grouped analysis of national observational, non-interventional studies initiated in clinical practice was performed to assess the effectiveness of triptorelin in reducing moderate or severe LUTSs, measured using the International Prostate Symptom Score (IPSS) in men with advanced or metastatic PCa...
July 2017: Therapeutic Advances in Urology
https://www.readbyqxmd.com/read/28747995/assessment-of-inhibitory-effects-on-major-human-cytochrome-p450-enzymes-by-spasmolytics-used-in-the-treatment-of-overactive-bladder-syndrome
#12
Dominik Dahlinger, Sevinc Aslan, Markus Pietsch, Sebastian Frechen, Uwe Fuhr
BACKGROUND: The objective of this study was to examine the inhibitory potential of darifenacin, fesoterodine, oxybutynin, propiverine, solifenacin, tolterodine and trospium chloride on the seven major human cytochrome P450 enzymes (CYP) by using a standardized and validated seven-in-one cytochrome P450 cocktail inhibition assay. METHODS: An in vitro cocktail of seven highly selective probe substrates was incubated with human liver microsomes and varying concentrations of the seven test compounds...
July 2017: Therapeutic Advances in Urology
https://www.readbyqxmd.com/read/28392837/denosumab-treatment-in-the-management-of-patients-with-advanced-prostate-cancer-clinical-evidence-and-experience
#13
REVIEW
Miriam Hegemann, Jens Bedke, Arnulf Stenzl, Tilman Todenhöfer
Osteoprotective therapies have become an essential component in the management of advanced prostate cancer (PC) patients as bone metastases (BMs) have a major impact on morbidity and mortality. Denosumab is a fully humanized antibody targeting the receptor activator of nuclear factor κB ligand (RANKL), which has been approved by the European Medicines Agency (EMA) in Europe and the United States (US) Food and Drug Administration (FDA) in the US for prevention of skeletal-related events (SREs) in patients with solid tumors and BMs, including PC...
March 2017: Therapeutic Advances in Urology
https://www.readbyqxmd.com/read/28392836/androgen-deprivation-therapy-in-the-treatment-of-locally-advanced-nonmetastatic-prostate-cancer-practical-experience-and-a-review-of-the-clinical-trial-evidence
#14
REVIEW
Fouad Aoun, Ali Bourgi, Elias Ayoub, Elie El Rassy, Roland van Velthoven, Alexandre Peltier
Following new scientific insights, initial management for patients with high-risk nonmetastatic prostate cancer has changed considerably and rapidly over the last few years. Several clinical and pathologic variables should be taken into account when deciding the best treatment choice for those patients. These variables are summarized and discussed in detail. High radiation doses to the prostate are essential to achieve good local control in patients with high-risk nonmetastatic disease. Addition of androgen deprivation therapy (ADT) to radiation therapy has significantly improved overall survival and cancer-specific survival compared with radiation therapy alone without significantly increasing toxicity...
March 2017: Therapeutic Advances in Urology
https://www.readbyqxmd.com/read/28392835/bovine-serum-albumin-glutaraldehyde-bioglue-%C3%A2-tissue-adhesive-versus-standard-renorrhaphy-following-renal-mass-enucleation-a-retrospective-comparison
#15
Zaher Bahouth, Boaz Moskovitz, Sarel Halachmi, Ofer Nativ
BACKGROUND: To present the operative and post-operative comparison between patients who underwent tumor-bed closure with sutures compared with bovine serum albumin-glutaraldehyde (BioGlue(®)) tissue sealant only. METHODS: We retrospectively analyzed data from our ongoing database of 507 eligible patients who underwent open NSS nephron-sparing surgery in our department between January 1995 and May 2014. Patients had tumor-bed closure with sealant adhesive (255 patients) or standard suture technique (252 patients)...
March 2017: Therapeutic Advances in Urology
https://www.readbyqxmd.com/read/28203288/nebivolol-versus-other-beta-blockers-in-patients-with-hypertension-and-erectile-dysfunction
#16
REVIEW
Randall P Sharp, Barry J Gales
Erectile dysfunction (ED) impacts over 100 million men worldwide and occurs at a higher incidence in men with hypertension. Beta blockers are one of several antihypertensive drug classes associated with ED. Nebivolol is a beta blocker with vasodilating properties mediated through endothelial release of nitric oxide which facilitates penile erection. Thus, nebivolol may offer an advantage over other beta blockers in the patient with hypertension and ED. A literature search comparing nebivolol with other beta blockers identified four European studies of limited duration, with the longest study being 28 weeks...
February 2017: Therapeutic Advances in Urology
https://www.readbyqxmd.com/read/28203287/specific-immunotherapy-in-renal-cancer-a-systematic-review
#17
REVIEW
Armin Hirbod-Mobarakeh, Hesam Addin Gordan, Zahra Zahiri, Mohammad Mirshahvalad, Sima Hosseinverdi, Brian I Rini, Nima Rezaei
BACKGROUND: Renal cell cancer (RCC) is the tenth most common malignancy in adults. In recent years, several approaches of active and passive immunotherapy have been studied extensively in clinical trials of patients with RCC. The aim of this systematic review was to assess the clinical efficacy of various approaches of specific immunotherapy in patients with RCC. METHODS: We searched Medline, Scopus, CENTRAL, TRIP, DART, OpenGrey and ProQuest without any language filter through to 9 October 2015...
February 2017: Therapeutic Advances in Urology
https://www.readbyqxmd.com/read/28203286/direct-visual-internal-urethrotomy-for-isolated-post-urethroplasty-strictures-a-retrospective-analysis
#18
Elizabeth Timbrook Brown, Stephen Mock, Roger Dmochowski, W Stuart Reynolds, Douglas Milam, Melissa R Kaufman
BACKGROUND: Urethroplasty is often successful for the treatment of male urethral stricture disease, but limited data exists on recurrence management. Our goal was to evaluate direct visual internal urethrotomy (DVIU) as a treatment option for isolated, recurrent strictures after urethroplasty. METHODS: We retrospectively identified male patients who underwent urethroplasty from 1999 to 2013 and developed an isolated, recurrent stricture at the urethroplasty site treated with DVIU...
February 2017: Therapeutic Advances in Urology
https://www.readbyqxmd.com/read/28042310/vinflunine-in-the-treatment-of-advanced-urothelial-cancer-clinical-evidence-and-experience
#19
REVIEW
Holger Gerullis, Friedhelm Wawroschek, Claus-Henning Köhne, Thorsten Holger Ecke
Vinflunine (VFL) has been approved in Europe for second-line treatment of metastatic and advanced urothelial cancer after failure of platin-containing therapy. Since approval, the drug has been investigated in few clinical trials. Most of the currently available reports describe experiences with VFL in a daily clinical setting. This review gives a short overview on clinical experiences and clinical trials involving VFL since the approval of this drug in 2009.
January 2017: Therapeutic Advances in Urology
https://www.readbyqxmd.com/read/28042309/the-link-between-vascular-dysfunction-bladder-ischemia-and-aging-bladder-dysfunction
#20
REVIEW
Karl-Erik Andersson, Donna B Boedtkjer, Axel Forman
The vascular supply to the human bladder is derived mainly from the superior and inferior vesical arteries, the latter being directly connected to the internal iliac artery. Aging is associated with an impairment of blood vessel function and changes may occur in the vasculature at the molecular, cellular and functional level. Pelvic arterial insufficiency may play an important role in the development of bladder dysfunctions such as detrusor overactivity (DO) and the overactive bladder syndrome. Chronic ischemia-related bladder dysfunction may progress to bladder underactivity and it would be desirable to treat not only lower urinary tract symptoms (LUTS) induced by chronic ischemia, but also the progression of the morphological bladder changes...
January 2017: Therapeutic Advances in Urology
journal
journal
42175
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"